Barclays PLC Sells 157,105 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Barclays PLC lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 32.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 325,921 shares of the biopharmaceutical company’s stock after selling 157,105 shares during the quarter. Barclays PLC owned 0.31% of Regeneron Pharmaceuticals worth $183,256,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. State Street Corp increased its stake in Regeneron Pharmaceuticals by 0.9% in the second quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock valued at $2,536,801,000 after acquiring an additional 42,343 shares during the period. Dodge & Cox lifted its stake in Regeneron Pharmaceuticals by 64.6% during the second quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after purchasing an additional 1,502,198 shares during the period. Franklin Resources Inc. lifted its stake in Regeneron Pharmaceuticals by 1.6% during the second quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company’s stock worth $1,214,585,000 after purchasing an additional 36,821 shares during the period. Loomis Sayles & Co. L P boosted its holdings in Regeneron Pharmaceuticals by 18.6% during the second quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock valued at $1,019,062,000 after purchasing an additional 305,089 shares in the last quarter. Finally, Norges Bank acquired a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $628,151,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on REGN. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Royal Bank Of Canada lifted their target price on shares of Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a research note on Monday, March 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Barclays initiated coverage on Regeneron Pharmaceuticals in a research report on Friday. They issued an “overweight” rating and a $923.00 price objective for the company. Finally, Canaccord Genuity Group boosted their price objective on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $802.27.

Regeneron Pharmaceuticals Trading Down 0.7%

Shares of REGN opened at $759.82 on Friday. The stock’s fifty day simple moving average is $770.81 and its 200-day simple moving average is $687.94. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $80.33 billion, a PE ratio of 18.28, a price-to-earnings-growth ratio of 2.06 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the company posted $12.07 EPS. The company’s revenue was up 2.5% compared to the same quarter last year. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were issued a dividend of $0.94 per share. The ex-dividend date of this dividend was Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total value of $1,585,066.72. Following the transaction, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. This represents a 32.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This trade represents a 49.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.